The link to diabetes is questionable and inconsequential.
World-renowned researchers from the Charles E. Schmidt College of Medicine at Florida Atlantic University as well as Harvard Medical School address the possible but unproven link between statins and diabetes, as well as the implications of prescription of statins for clinicians and their patients, in a commentary published in the prestigious American Journal of Medicine. The editor-in-chief of the journal published the commentary and an editorial he wrote online ahead of print.
“The totality of evidence clearly indicates that the more widespread and appropriate utilization of statins, as adjuncts, not alternatives to therapeutic lifestyle changes, will yield net benefits in the treatment and primary prevention of heart attacks and strokes, including among high, medium and low risk patients unwilling or unable to adopt therapeutic lifestyle changes,” said Charles H. Hennekens, M.D, Dr.P.H., the first Sir Richard Doll professor and senior academic advisor to the dean, the Charles E. Schmidt College of Medicine at FAU.
- Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physicians.
- Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients.
- Too Few U.S. Young Adults Being Prescribed Needed Statins.
- Meta-Analysis: Statins Cut Risk of Advanced Colorectal Adenoma.
In the accompanying editorial, Joseph S. Alpert, M.D., editor-in-chief and a renowned cardiologist and professor of medicine at the University of Arizona School of Medicine, reinforces these important and timely clinical and public health challenges in treatment and primary prevention.
“There is no threshold for low density lipoprotein cholesterol below which there are no net benefits of statins either in the treatment or primary prevention of heart attacks and strokes,” said Alpert.
The authors and editorialist express grave concerns that there will be many needless premature deaths as well as preventable heart attacks and strokes if patients who would clearly benefit from statins are not prescribed the drug, refuse to take the drug, or stop using the drug because of ill-advised adverse publicity about benefits and risks, which may include misplaced concerns about the possible but unproven small risk of diabetes.